Biogen gets EU antitrust questions over multiple-sclerosis drug
US biotech company Biogen is the target of an EU investigation regarding its compliance with antitrust laws for a multiple sclerosis treatment, MLex has learned. Last month, it was quizzed by...To view the full article, register now.
Already a subscriber? Click here to view full article